Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation

Medical University of Vienna

Overview

The purpose of the study is to compare the effects of recombinant factor VIIa (NovoSeven) on restoring coagulation activation between patients with hemophilia A and antibodies to factor VIII and normal subjects (controls) by use of an in vivo method.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Conditions

Hemophilia A

Interventions

NovoSevenDRUG

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients with hemophilia A and current antibodies to factor VIII - Exclusion Criteria: * Life-threatening hemorrhage * Severe liver failure * Any other severe co-morbidity (including diabetes mellitus, renal failure, cancer, septicemia, disseminated intravascular coagulation, crush injury) * Exposure to other haemostatic drugs during the previous 7 days * Hypersensitivity to hamster, mouse or bovine proteins * Known or suspected allergy to NovoSeven or any of its components

Locations (1)

Medical University of Vienna

Vienna, Austria

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.